Bristol-Myers Squibb Company

Bristol-Myers Squibb Company(BMY)股票分析

$59.750

-0.807 (-1.35%)收盘时

Loading chart…
最高
61.427
开盘
61.100
成交量加权均价
60.24
成交量
13.77M
市值
84.14B
最低
59.540
成交额
829.59M
企业价值/息税折旧摊销前利润(TTM)
7.88

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).

AI 分析 of Bristol-Myers Squibb Company (BMY)

买入

Bristol-Myers Squibb Co is a good buy right now due to its current price of $59.75, which is well below the analyst price target of $76 from Jefferies, indicating a potential upside of 27%. Additionally, the forward P/E ratio of 9.36 suggests that the stock is undervalued compared to its earnings potential. The main risk comes from the company's net margin of 14.6%, which, while improved, indicates ongoing challenges in profitability.

分析师评级(22)

-6.51% 下跌空间
持有
9 买入
11 持有
2 卖出
当前: 59.75
最低
37.00
平均
55.86
最高
68.00

Jefferies

2026-10-12

目标价

$76

买入

William Blair

2026-10-12

目标价

—

Market Perform

BofA

2026-10-09

目标价

$66

买入

Cantor Fitzgerald

2026-10-08

目标价

$53

中性

Morgan Stanley

2026-10-07

目标价

$41

减持

估值指标

Bristol-Myers Squibb Company(BMY)当前预期市盈率为 9.36,5 年平均预期市盈率为 11.38。

预期市盈率

合理
5 年均值 P/E
11.38
当前P/E
9.36
高估
24.94
低估
-2.18

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
10.20
当前EV/EBITDA
7.88
高估
14.39
低估
6.02

预期市销率

合理
5 年均值 P/S
2.67
当前P/S
2.52
高估
3.19
低估
2.16

Alphio AI 对 BMY 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%BMY

$44.66

情景价格

基

基准

基准 · 50%BMY

$40.66

情景价格

悲

悲观

悲观 · 25%BMY

$35.77

情景价格

持有 BMY 的大户

T

Turtle Creek Management, LLC

+ 持有BMY

+19.26%

3个月收益率

B

Blackhill Capital, Inc

+ 持有BMY

+10.72%

3个月收益率

S

Sofinnova Investments, Inc.

+ 持有BMY

+7.79%

3个月收益率

C

Cbus Industry Superannuation Fund

+ 持有BMY

+6.73%

3个月收益率

A

Acadian Asset Management LLC

+ 持有BMY

+5.83%

3个月收益率

C

CWA Asset Management Group, LLC

+ 持有BMY

+5.40%

3个月收益率

事件时间线

2026-10-15 (ET)

14:30:00

Applied Intuition Valued at $30B, Plans to Raise Over $1B

2026-10-12 (ET)

14:00:00

RBC Analyst Calls Bristol Myers Drug Results Positive

09:00:00

S&P 500 Futures Mixed as Oil Prices Rise

07:00:00

Bristol Myers Squibb Announces Phase 3 Trial Results for Admilparant

07:00:00

Bristol Myers Squibb Announces Positive ACTION-1 Trial Results

资讯

BMY 常见问题 —— 由 Alphio AI 解答

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Bristol-Myers Squibb Co is a good buy right now due to its current price of $59.75, which is well below the analyst price target of $76 from Jefferies, indicating a potential upside of 27%. Additionally, the forward P/E ratio of 9.36 suggests that the stock is undervalued compared to its earnings potential. The main risk comes from the company's net margin of 14.6%, which, while improved, indicates ongoing challenges in profitability.

22 analysts cover BMY: 9 rate it Buy, 11 Hold and 2 Sell. The average price target is 55.86.

molten_vortex2026/9/26

Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says. A tidal wave of innovation in biotechnology is improving patient outcomes, transforming the industry's prospects, and lifting long-suffering biotech shares. Spurred by therapeutic breakthroughs and new-product launches, investors have bid up the iShares Biotechnology, or IBB, by 24% this year, while the State Street SPDR S&P Biotech ETF, or XBI, has risen 28%, more than twice the gain of the S&P 500. Large pharmaceutical companies are also paying attention. They have been striking licensing deals with smaller biotechs and scooping up whole companies in a bid to rebuild their pipelines and replace blockbuster drugs facing patent expirations. $MRNA $MRK $RVMD $BMY $SMMT

展开
RektEddy2026/9/15

$PGR $SYK $BMY Many people enter the crypto space chasing quick profits, but real, consistent success is built on knowledge, discipline, and the right guidance. That’s where having a reliable mentor makes all the difference. Craig has played a key role in helping me understand the markets with more clarity and confidence. His approach to trading goes beyond signals, it’s about building structure, managing risk, and staying focused on long-term growth. With his guidance and his YouTube videos, I’ve been able to make smarter decisions, avoid emotional trading, and stay consistent even in volatile conditions. The shift in mindset alone has been a game changer.

展开
注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易